Adiponectin plasma levels are increased by atorvastatin treatment in subjects at high cardiovascular risk

Luis M. Blanco-Colio, Jose L. Martín-Ventura, Carmen Gómez-Guerrero, Xavier Masramon, Eduardo de Teresa, C. Farsang, Allan Gaw, GianFranco Gensini, Lawrence A. Leiter, Anatoly Langer, Jesús Egido

Research output: Contribution to journalArticle

37 Citations (Scopus)

Abstract

Adiponectin can suppress atherogenesis by inhibiting the adherence of monocytes, reducing their phagocytic activity, and suppressing the accumulation of modified lipoproteins in the vascular wall. Contradictory data have been reported about the effect of statins on adiponectin plasma levels. In this work, adiponectin plasma levels were measured in 102 statin-free subjects from the Spanish population of the Achieve Cholesterol Targets Fast with Atorvastatin Stratified Titration (ACTFAST) study, a 12-week, prospective, multi-centre, open-label trial which enrolled subjects with coronary heart disease, coronary heart disease-equivalent or a 10-year coronary heart disease risk > 20%. Subjects were assigned to atorvastatin (10-80 mg/day) based on low-density lipoprotein (LDL)-cholesterol concentration at screening. For comparison, age and gender-matched blood donors (N = 40) were used as controls. Control subjects did not present hypertension, hypercholesterolemia, diabetes, metabolic syndrome and history of cardiovascular diseases. Adiponectin levels were diminished in patients at high cardiovascular risk compared with control subjects [4166 (3661-4740) vs 5806 (4764-7075) ng/ml respectively; geometric mean (95% CI); P <0.0001]. In the whole population, atorvastatin treatment increased adiponectin levels [9.7 (3.2-16.7);% Change (95% CI); P = 0.003]. This increment was in a dose-dependent manner; maximal effect observed with atorvastatin 80 mg/d [24.7 (5.7-47.1); P = 0.01]. Adiponectin concentrations were positively correlated with high-density lipoprotein-cholesterol both before and after atorvastatin treatment. No association was observed between adiponectin and LDL-cholesterol before and after atorvastatin treatment. In conclusion, atorvastatin increased adiponectin plasma levels in subjects at high cardiovascular risk, revealing a novel anti-inflammatory effect of this drug.

Original languageEnglish
Pages (from-to)259-265
Number of pages7
JournalEuropean Journal of Pharmacology
Volume586
Issue number1-3
DOIs
Publication statusPublished - May 31 2008

Fingerprint

Adiponectin
Coronary Disease
Hydroxymethylglutaryl-CoA Reductase Inhibitors
Therapeutics
LDL Cholesterol
Atorvastatin Calcium
Hypercholesterolemia
Blood Donors
HDL Cholesterol
Population
Lipoproteins
Blood Vessels
Monocytes
Atherosclerosis
Anti-Inflammatory Agents
Cardiovascular Diseases
Cholesterol
Hypertension
Pharmaceutical Preparations

Keywords

  • Adiponectin
  • Cholesterol-lowering drugs
  • High cardiovascular risk
  • Inflammation

ASJC Scopus subject areas

  • Cellular and Molecular Neuroscience
  • Pharmacology

Cite this

Blanco-Colio, L. M., Martín-Ventura, J. L., Gómez-Guerrero, C., Masramon, X., de Teresa, E., Farsang, C., ... Egido, J. (2008). Adiponectin plasma levels are increased by atorvastatin treatment in subjects at high cardiovascular risk. European Journal of Pharmacology, 586(1-3), 259-265. https://doi.org/10.1016/j.ejphar.2008.02.042

Adiponectin plasma levels are increased by atorvastatin treatment in subjects at high cardiovascular risk. / Blanco-Colio, Luis M.; Martín-Ventura, Jose L.; Gómez-Guerrero, Carmen; Masramon, Xavier; de Teresa, Eduardo; Farsang, C.; Gaw, Allan; Gensini, GianFranco; Leiter, Lawrence A.; Langer, Anatoly; Egido, Jesús.

In: European Journal of Pharmacology, Vol. 586, No. 1-3, 31.05.2008, p. 259-265.

Research output: Contribution to journalArticle

Blanco-Colio, LM, Martín-Ventura, JL, Gómez-Guerrero, C, Masramon, X, de Teresa, E, Farsang, C, Gaw, A, Gensini, G, Leiter, LA, Langer, A & Egido, J 2008, 'Adiponectin plasma levels are increased by atorvastatin treatment in subjects at high cardiovascular risk', European Journal of Pharmacology, vol. 586, no. 1-3, pp. 259-265. https://doi.org/10.1016/j.ejphar.2008.02.042
Blanco-Colio, Luis M. ; Martín-Ventura, Jose L. ; Gómez-Guerrero, Carmen ; Masramon, Xavier ; de Teresa, Eduardo ; Farsang, C. ; Gaw, Allan ; Gensini, GianFranco ; Leiter, Lawrence A. ; Langer, Anatoly ; Egido, Jesús. / Adiponectin plasma levels are increased by atorvastatin treatment in subjects at high cardiovascular risk. In: European Journal of Pharmacology. 2008 ; Vol. 586, No. 1-3. pp. 259-265.
@article{7925d859d9734826b6c05fdb187d18d7,
title = "Adiponectin plasma levels are increased by atorvastatin treatment in subjects at high cardiovascular risk",
abstract = "Adiponectin can suppress atherogenesis by inhibiting the adherence of monocytes, reducing their phagocytic activity, and suppressing the accumulation of modified lipoproteins in the vascular wall. Contradictory data have been reported about the effect of statins on adiponectin plasma levels. In this work, adiponectin plasma levels were measured in 102 statin-free subjects from the Spanish population of the Achieve Cholesterol Targets Fast with Atorvastatin Stratified Titration (ACTFAST) study, a 12-week, prospective, multi-centre, open-label trial which enrolled subjects with coronary heart disease, coronary heart disease-equivalent or a 10-year coronary heart disease risk > 20{\%}. Subjects were assigned to atorvastatin (10-80 mg/day) based on low-density lipoprotein (LDL)-cholesterol concentration at screening. For comparison, age and gender-matched blood donors (N = 40) were used as controls. Control subjects did not present hypertension, hypercholesterolemia, diabetes, metabolic syndrome and history of cardiovascular diseases. Adiponectin levels were diminished in patients at high cardiovascular risk compared with control subjects [4166 (3661-4740) vs 5806 (4764-7075) ng/ml respectively; geometric mean (95{\%} CI); P <0.0001]. In the whole population, atorvastatin treatment increased adiponectin levels [9.7 (3.2-16.7);{\%} Change (95{\%} CI); P = 0.003]. This increment was in a dose-dependent manner; maximal effect observed with atorvastatin 80 mg/d [24.7 (5.7-47.1); P = 0.01]. Adiponectin concentrations were positively correlated with high-density lipoprotein-cholesterol both before and after atorvastatin treatment. No association was observed between adiponectin and LDL-cholesterol before and after atorvastatin treatment. In conclusion, atorvastatin increased adiponectin plasma levels in subjects at high cardiovascular risk, revealing a novel anti-inflammatory effect of this drug.",
keywords = "Adiponectin, Cholesterol-lowering drugs, High cardiovascular risk, Inflammation",
author = "Blanco-Colio, {Luis M.} and Mart{\'i}n-Ventura, {Jose L.} and Carmen G{\'o}mez-Guerrero and Xavier Masramon and {de Teresa}, Eduardo and C. Farsang and Allan Gaw and GianFranco Gensini and Leiter, {Lawrence A.} and Anatoly Langer and Jes{\'u}s Egido",
year = "2008",
month = "5",
day = "31",
doi = "10.1016/j.ejphar.2008.02.042",
language = "English",
volume = "586",
pages = "259--265",
journal = "European Journal of Pharmacology",
issn = "0014-2999",
publisher = "Elsevier",
number = "1-3",

}

TY - JOUR

T1 - Adiponectin plasma levels are increased by atorvastatin treatment in subjects at high cardiovascular risk

AU - Blanco-Colio, Luis M.

AU - Martín-Ventura, Jose L.

AU - Gómez-Guerrero, Carmen

AU - Masramon, Xavier

AU - de Teresa, Eduardo

AU - Farsang, C.

AU - Gaw, Allan

AU - Gensini, GianFranco

AU - Leiter, Lawrence A.

AU - Langer, Anatoly

AU - Egido, Jesús

PY - 2008/5/31

Y1 - 2008/5/31

N2 - Adiponectin can suppress atherogenesis by inhibiting the adherence of monocytes, reducing their phagocytic activity, and suppressing the accumulation of modified lipoproteins in the vascular wall. Contradictory data have been reported about the effect of statins on adiponectin plasma levels. In this work, adiponectin plasma levels were measured in 102 statin-free subjects from the Spanish population of the Achieve Cholesterol Targets Fast with Atorvastatin Stratified Titration (ACTFAST) study, a 12-week, prospective, multi-centre, open-label trial which enrolled subjects with coronary heart disease, coronary heart disease-equivalent or a 10-year coronary heart disease risk > 20%. Subjects were assigned to atorvastatin (10-80 mg/day) based on low-density lipoprotein (LDL)-cholesterol concentration at screening. For comparison, age and gender-matched blood donors (N = 40) were used as controls. Control subjects did not present hypertension, hypercholesterolemia, diabetes, metabolic syndrome and history of cardiovascular diseases. Adiponectin levels were diminished in patients at high cardiovascular risk compared with control subjects [4166 (3661-4740) vs 5806 (4764-7075) ng/ml respectively; geometric mean (95% CI); P <0.0001]. In the whole population, atorvastatin treatment increased adiponectin levels [9.7 (3.2-16.7);% Change (95% CI); P = 0.003]. This increment was in a dose-dependent manner; maximal effect observed with atorvastatin 80 mg/d [24.7 (5.7-47.1); P = 0.01]. Adiponectin concentrations were positively correlated with high-density lipoprotein-cholesterol both before and after atorvastatin treatment. No association was observed between adiponectin and LDL-cholesterol before and after atorvastatin treatment. In conclusion, atorvastatin increased adiponectin plasma levels in subjects at high cardiovascular risk, revealing a novel anti-inflammatory effect of this drug.

AB - Adiponectin can suppress atherogenesis by inhibiting the adherence of monocytes, reducing their phagocytic activity, and suppressing the accumulation of modified lipoproteins in the vascular wall. Contradictory data have been reported about the effect of statins on adiponectin plasma levels. In this work, adiponectin plasma levels were measured in 102 statin-free subjects from the Spanish population of the Achieve Cholesterol Targets Fast with Atorvastatin Stratified Titration (ACTFAST) study, a 12-week, prospective, multi-centre, open-label trial which enrolled subjects with coronary heart disease, coronary heart disease-equivalent or a 10-year coronary heart disease risk > 20%. Subjects were assigned to atorvastatin (10-80 mg/day) based on low-density lipoprotein (LDL)-cholesterol concentration at screening. For comparison, age and gender-matched blood donors (N = 40) were used as controls. Control subjects did not present hypertension, hypercholesterolemia, diabetes, metabolic syndrome and history of cardiovascular diseases. Adiponectin levels were diminished in patients at high cardiovascular risk compared with control subjects [4166 (3661-4740) vs 5806 (4764-7075) ng/ml respectively; geometric mean (95% CI); P <0.0001]. In the whole population, atorvastatin treatment increased adiponectin levels [9.7 (3.2-16.7);% Change (95% CI); P = 0.003]. This increment was in a dose-dependent manner; maximal effect observed with atorvastatin 80 mg/d [24.7 (5.7-47.1); P = 0.01]. Adiponectin concentrations were positively correlated with high-density lipoprotein-cholesterol both before and after atorvastatin treatment. No association was observed between adiponectin and LDL-cholesterol before and after atorvastatin treatment. In conclusion, atorvastatin increased adiponectin plasma levels in subjects at high cardiovascular risk, revealing a novel anti-inflammatory effect of this drug.

KW - Adiponectin

KW - Cholesterol-lowering drugs

KW - High cardiovascular risk

KW - Inflammation

UR - http://www.scopus.com/inward/record.url?scp=43749111768&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=43749111768&partnerID=8YFLogxK

U2 - 10.1016/j.ejphar.2008.02.042

DO - 10.1016/j.ejphar.2008.02.042

M3 - Article

C2 - 18374327

AN - SCOPUS:43749111768

VL - 586

SP - 259

EP - 265

JO - European Journal of Pharmacology

JF - European Journal of Pharmacology

SN - 0014-2999

IS - 1-3

ER -